Effectiveness Study Low-Dose Naltrexone Versus ARV's for HIV+

In the vast majority of those infected with HIV virus who are untreated, there is deterioration in immune health over a period of months or years inevitably leading to full-blown AIDS and demise. Treatment with ARV\'s stop or slow down this deterioration if started before a certain degree of progression occurs and has saved millions of lives. The investigators\' study hypothesis is that effectiveness of a very low dose of an FDA-approved medication, naltrexone hydrochloride, (Low-Dose Naltrexone, or LDN) will compare favorably to ARV\'s to prevent progression of HIV+ toward immune deterioration and full-blown AIDS.